Clinical study shows association between results of ChemoFx and RFS of cervical cancer patients

A clinical study reporting an association between the results of the ChemoFx^® chemoresponse assay and recurrence free survival (RFS) of cervical cancer patients has been accepted for publication by Gynecologic Oncology. Initial findings were presented at the 14^th Biennial Meeting of the International Gynecologic Cancer Society (IGCS) in Vancouver October 13-16, 2012.

“These data show a significant correlation between assay prediction of response and progression free interval”

The independent study on the assay was conducted by Perry W. Grigsby, M.D., Professor of Radiation Oncology at the Washington University School of Medicine in St Louis, Missouri. Dr. Grigsby is known for his clinical research in gynecologic cancers and was most recently listed in America's Top Doctors 2007-2012.

The study titled, In Vitro Chemoresponse to Cisplatin and Outcomes in Cervical Cancer, analyzedcervical cancer patients with stage Ib2 to IIIb disease who were treated with weekly cisplatin chemoradiation (chemoRT) and received pre-treatment cisplatin chemoresponse testing with ChemoFx.

Initial findings presented revealed the 2-year recurrence free survivals (RFS) for patients who scored as responsive or intermediately responsive to cisplatin via ChemoFx were 87%, compared to 58% for those who were scored as non-responsive to cisplatin (p = 0.047). This 50% increase in response clearly demonstrates the significant impact this assay could have on patient outcomes.

The data presented at IGCS concluded that the use of ChemoFx to perform a chemoresponse analysis of cervical cancer prior to treatment was predictive of RFS outcomes in patients treated with weekly cisplatin chemoRT. These results support the use of ChemoFx for helping with treatment decisions for cervical cancer patients.

"These data show a significant correlation between assay prediction of response and progression free interval," says Dr. Perry W. Grigsby. "From a clinical standpoint, the additional information that ChemoFx provides informs clinicians when choosing an effective second line agent for the patient, with the ultimate goal of receiving maximum benefit."